3-(2-carboxy-3-hydroxyamino-propyl)-benzoic acid | 378243-12-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(2-carboxy-3-hydroxyamino-propyl)-benzoic acid
• 英文别名: 3-[2-Carboxy-3-(hydroxyamino)propyl]benzoic acid
• CAS: 378243-12-0
• 化学式: C₁₁H₁₃NO₅
• 分子量: 239.228
• InChiKey: IVHMGCLMENVIEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Naaladase inhibitors for treating retinal disorders and glaucoma
  申请人：——

  公开号：US20030036534A1

  公开（公告）日：2003-02-20

  The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.

  本发明涉及使用NAALADase抑制剂治疗视网膜疾病或青光眼的药物组合物和方法。
• [EN] N,N-BRIDGED, NITROGEN-SUBSTITUTED CARBACYCLIC INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS<br/>[FR] INDOLOCARBAZOLES CARBACYCLIQUES A PONT N,N ET SUBSTITUTION AZOTE, UTILES COMME INHIBITEURS DE PROTEINE KINASE
  申请人：NAD AG

  公开号：WO2004048384A1

  公开（公告）日：2004-06-10

  The present invention relates to novel protein kinase inhibitors with advantageous pharmaceutical properties, methods for their preparation, intermediates thereof and pharmaceutical compositions comprising the same, reagents containing the same, and methods of using the same as therapeutics, particularly in CNS diseases.

  本发明涉及具有有利药理特性的新型蛋白激酶抑制剂，其制备方法，中间体及包含其的药物组合物，含有相同物质的试剂，以及将其用作治疗剂的方法，尤其是在中枢神经系统疾病中的应用。
• Hydroxamic acids and acyl hydroxamines as NAALADase inhibitors
  申请人：Tsukamoto Takashi

  公开号：US20060009525A1

  公开（公告）日：2006-01-12

  This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-β activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.

  本发明涉及新化合物、制药组合物和诊断试剂盒，包括这些化合物，并使用这些化合物抑制NAALADase酶活性、检测NAALADase水平改变的疾病、影响神经元活动、影响TGF-β活性、抑制血管生成，并治疗谷氨酸异常、神经病、疼痛、强迫症、前列腺疾病、癌症和青光眼。
• Naaladase inhibitors for treating opioid tolerance
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US20040186081A1

  公开（公告）日：2004-09-23

  The present invention relates to pharmaceutical compositions and methods for treating opioid tolerance using NAALADase inhibitors.

  本发明涉及制药组合物和使用NAALADase抑制剂治疗阿片类药物耐受性的方法。
• NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1292601A2

  公开（公告）日：2003-03-19